Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Bedford, Massachusetts, USA.
The Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
Telemed J E Health. 2024 Feb;30(2):518-526. doi: 10.1089/tmj.2023.0010. Epub 2023 Aug 24.
Technology-based programs can be cost-effective in the management of chronic obstructive pulmonary disease (COPD). However, cost-effectiveness estimates always contain some uncertainty, and decisions based upon them carry some risk. We conducted a value of information (VOI) analysis to estimate the value of additional research of a web-based self-management intervention for COPD to reduce the costs associated with uncertainty. We used a 10,000-iteration cost-effectiveness model from the health care payer perspective to calculate the expected value of perfect information (EVPI) at the patient- and population-level. An opportunity loss was incurred when the web-based intervention did not produce a greater net monetary benefit than usual care in an iteration. We calculated the probability of opportunity loss and magnitude of opportunity costs as a function of baseline health utility. We aggregated opportunity costs over the projected incident population of inpatient COPD patients over 10 years and estimated it as a function of the willingness-to-pay (WTP) threshold. Costs are in 2022 U.S. Dollars. Opportunity losses were found in 22.7% of the iterations. The was $78 per patient (95% confidence interval: $75-$82). The probability that the intervention was the optimal strategy varied across baseline health utilities. The was $506,666,882 over 10 years for a WTP of $50,000. Research estimated to cost up to $500 million would be warranted to reduce uncertainty. Future research could focus on identifying the impact of baseline health utilities to maximize the cost savings of the intervention. Other considerations for future research priorities include implementation efforts for technology-based interventions.
基于技术的方案在慢性阻塞性肺疾病(COPD)的管理中具有成本效益。然而,成本效益估计总是包含一些不确定性,基于这些估计做出的决策存在一定的风险。我们进行了一项价值信息(VOI)分析,以估计针对 COPD 的基于网络的自我管理干预措施的额外研究的价值,以降低与不确定性相关的成本。我们使用了一种从医疗保健支付者角度出发的 10000 次迭代成本效益模型,来计算患者和人群层面的完全信息价值(EVPI)的预期值。如果在迭代中,基于网络的干预措施没有比常规护理产生更大的净货币效益,就会产生机会损失。我们计算了机会损失的概率和机会成本的大小,作为基线健康效用的函数。我们将机会成本汇总到预计在 10 年内患有住院 COPD 患者的预计发病人群中,并根据支付意愿(WTP)阈值对其进行了估计。成本以 2022 年的美元计算。在 22.7%的迭代中发现了机会损失。增量成本为每位患者 78 美元(95%置信区间:75-82 美元)。该干预措施是最优策略的概率因基线健康效用而异。在 WTP 为 50000 美元的情况下,10 年内为 5066666882 美元。研究估计,要降低不确定性,需要进行高达 5 亿美元的研究。未来的研究可以集中在确定基线健康效用的影响上,以最大限度地降低干预措施的成本节约。未来研究重点的其他考虑因素包括基于技术的干预措施的实施工作。